Read This First
This page is not built on clinical evidence. It is built on the FDA's July 2026 evaluation, the analytical chemistry of seized product, and the regulatory record. What epitalon does in cells and mice is covered on the library entry; this page is about what is in the vial, and about a naming confusion that runs through the whole market.
Epitalon is a four-residue peptide, cheap to synthesise and hard to get wrong, sold under three spellings and confused, deliberately or otherwise, with a gland extract that carries all of the human data.1 For this compound the identity question is less "is the powder AEDG" than "is AEDG the thing the product page is describing."
Legal Status
Where Does Epitalon Stand?
Approved nowhere. No marketing authorisation, no monograph, not a component of any approved drug, and not in any national medical registry the FDA searched.1 Epithalamin, the extract it imitates, has been used clinically in Russia; that history does not transfer to the synthetic.
In the United States epitalon was placed in Category 2 of the FDA's interim compounding policy in September 2023 and is now listed among substances nominated but withdrawn.2
What Did the July 2026 Vote Change?
Nothing yet. On 24 July 2026 the Pharmacy Compounding Advisory Committee voted 7 to 4, with one abstention, to recommend epitalon free base and acetate for the 503A bulks list for insomnia, against the FDA's recommendation.3 The nominations proposed subcutaneous injections at 10 mg/mL and 3 mg/mL.1 The recommendation is advisory, the list can only be amended by rulemaking, and the FDA has not begun one. No pharmacy in the United States has a lawful basis on which to compound it.
The FDA's review also records that compounding with epitalon "can be traced back to at least 2018," when "a compounding pharmacy and its owner were sentenced for unlawful distribution of compounded prescription drugs, including epitalon," and that wellness clinics and concierge practices offer it as an anti-ageing agent, some claiming it comes from a compounding pharmacy the FDA could not identify.1
Product Identity
Epitalon, Epithalon, Epithalamin: Which Is Which?
| Name | What it is | What the human data belong to |
|---|---|---|
| Epitalon, epithalon, epithalone, AEDG | The synthetic tetrapeptide Ala-Glu-Asp-Gly. One spelling difference, one substance. | One 20-day sublingual study of melatonin metabolites in 40 shift workers1 |
| Epithalamin | A polypeptide extract of calf pineal gland, of undefined composition, developed in the Soviet era | The 12-year mortality study and the other elderly-patient trials4 |
| "Epitalon" on a product page citing a 12-year human study | The tetrapeptide, described with the extract's results | Not the product being sold |
The FDA noted the general problem in its own terms: it "has encountered multiple salts, and derivatives, including different active moieties, being marketed under the same common name," and inconsistent naming "can contribute to a potential safety risk for patients."1
What Did the FDA Find on Characterisation?
Both nominations came with certificates for the acetate salt, and on the basic identity fields they were consistent: the CAS numbers, formula and weight matched. What was missing was everything past identity: no impurity data, no aggregation data, no bioburden or endotoxin testing, and for the free base no usable solubility data. The FDA's conclusion was that neither form is well characterised for an injectable.1
For a tetrapeptide, that is the right emphasis. Four residues of natural amino acids leave little room to get the sequence wrong. What separates a research-grade powder from an injectable is whether it is sterile, pyrogen-free and free of synthesis residues, and no certificate the FDA saw addressed that.
What Has Been Found in Seized Product?
In 2015 the Belgian national laboratory reported identifying epitalon in two illegal pharmaceutical preparations seized by the authorities, describing it as a research tetrapeptide "assumed to be a potential treatment for cancer, old age and retinitis pigmentosa."5 That is the documented sighting: the compound in unlabelled or mislabelled preparations, in a customs seizure, a decade ago.
Purity Testing Versus Identity Testing
| Test | Question it answers | Question it cannot answer |
|---|---|---|
| HPLC purity | What proportion of the sample is one substance | Whether it is sterile or pyrogen-free |
| Mass spectrometry identity | Whether the mass matches AEDG, about 390 daltons | How much of the sample it represents; whether the acetate salt is what the label says |
| Endotoxin and bioburden | Whether the vial is safe to inject | Identity; missing from the certificates the FDA reviewed |
| Residual solvents and reagents | Whether synthesis chemicals remain | Rarely reported at all |
Certificates of Analysis
What a Certificate Is
A laboratory report on one batch. Read it for the laboratory's independence from the seller, the lot number and whether it matches the vial, the date, the substance named including free base or acetate, and, for this compound above all, whether endotoxin and sterility were tested.
What It Cannot Establish
That the vial in hand came from the batch tested. Its value rests on a chain of custody the buyer cannot inspect. A certificate is a PDF, and nothing about the format prevents reuse or fabrication; the FDA has documented fabricated labels on gray-market peptide products.6
"Research Use Only"
Does the Label Change Anything?
No. It is a liability position adopted by the seller, not a regulatory category. The FDA has held in warning letters that the disclaimer does not survive product copy establishing human use.7 A page describing telomere lengthening, "anti-ageing" and a ten-day injection protocol is describing human use.
The Protocol Problem
Where Do the Dosing Schedules Come From?
Community protocols for epitalon, typically a ten-day course of daily injections repeated once or twice a year, are modelled on the Russian clinical use of epithalamin and on the mouse studies, where the peptide was given on five consecutive days each month.8 No human study of injected epitalon has tested any schedule. A buyer following a "cycle" is following a translation of a mouse protocol through a different substance's clinical history.
Storage and Handling
What Is Known
No manufacturer-validated storage specification exists for any product a consumer can buy. A four-residue peptide of natural amino acids is robust as a dry powder; reconstituted solutions follow the ordinary rules, and the FDA's concern for injectables of this kind is aggregation and impurity-related immunogenicity rather than degradation.1
Multi-Dose Vials
The FDA's guidance for compounded injectables is to discard a multi-dose vial within 28 days of first use regardless of what remains, and to use a new sterile needle and syringe for every dose.6 A ten-day course from one vial sits inside that; a vial kept for the next cycle six months later does not.
Signs to Stop Rather Than Proceed
Injectable product with no sterility or endotoxin result on its certificate
A product page attributing human mortality data to epitalon; the data are epithalamin's, and a seller who does not know the difference does not know the product
Powder that does not dissolve cleanly, or a solution that is cloudy or discoloured
Injection-site reactions that grow with successive doses
Community Language
Epitalon, Epithalon, AEDG
The synthetic tetrapeptide. The subject of this page.
Epithalamin
The bovine pineal extract the tetrapeptide was designed to imitate. A different, undefined substance with its own clinical history.4
Bioregulator
The Russian programme's term for short peptides modelled on tissue extracts. A theoretical framework, not a regulatory category or an evidence grade.
Telomerase activator
The mechanism claimed from one 2003 cell culture paper, and the mechanism the FDA named as a cancer concern.1
Category 2
The FDA's interim classification for nominated compounding substances that may present significant safety risks. Epitalon was placed there in 2023 and is now listed as nominated but withdrawn.2
Certificate of analysis
A laboratory report on one batch. It describes the batch tested, not necessarily the vial received.
Related ONPEPS Coverage
Sources
US Food and Drug Administration. Epitalon-related bulk drug substances (epitalon (free base) and epitalon acetate): FDA presentation to the Pharmacy Compounding Advisory Committee, 24 July 2026. Docket FDA-2025-N-6895. fda.gov
US Food and Drug Administration. Category 2 of the Bulk Substances Nominated Under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act. Entry for epitalon. Content current as of 22 April 2026. fda.gov
ONPEPS. FDA peptide news July 2026: the only source you need. Records the 7 to 4 vote with one abstention on epitalon. onpeps.com
Korkushko OV, Khavinson VKh, Shatilo VB, Antonyuk-Shcheglova IA. Geroprotective effect of epithalamine (pineal gland peptide preparation) in elderly subjects with accelerated aging. Bull Exp Biol Med. 2006;142(3):356-359. Paywalled. pubmed.ncbi.nlm.nih.gov/17426848
Vanhee C, Moens G, Van Hoeck E, Deconinck E, De Beer JO. Identification of the small research tetra peptide Epitalon, assumed to be a potential treatment for cancer, old age and retinitis pigmentosa in two illegal pharmaceutical preparations. Drug Test Anal. 2015;7(3):259-264. Paywalled. doi.org/10.1002/dta.1771
US Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Drug Alerts and Statements. Cited for the agency's general guidance on multi-dose vials and fabricated labels. fda.gov
US Food and Drug Administration. Warning Letter: Gram Peptides. MARCS-CMS 721806, 31 March 2026. fda.gov
Anisimov VN, Khavinson VKh, Popovich IG, Zabezhinski MA, Alimova IN, Rosenfeld SV, et al. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology. 2003;4(4):193-202. Paywalled. pubmed.ncbi.nlm.nih.gov/14501183
Not Medical Advice
Epitalon holds no marketing authorisation for human use in any jurisdiction. If you are already using a product obtained outside a pharmacy, the route back to oversight is a clinician who knows what you have taken.
Regulatory sources verified 16 September 2026. The FDA had not acted on the July 2026 advisory recommendation as of that date, and the compounding record changes frequently. Re-verify before relying on any statement here.